Transarterial Chemoembolization (TACE): Indications, Procedure and Outcomes — Overview, Diagnosis & Treatment Options | MyMedicPlus

Transarterial chemoembolization (TACE) is a minimally invasive interventional radiology procedure that exploits the dual blood supply of the liver: while normal hepatocytes receive approximately 75% of their blood supply from the portal vein, hepatic tumors are predominantly fed by the hepatic artery. TACE delivers chemotherapy directly into the tumor-feeding hepatic artery via a coaxial microcatheter, followed by embolization of the arterial supply to achieve simultaneous chemotherapy exposure and ischemic tumor necrosis. Two main types exist: conventional TACE (cTACE) using doxorubicin or cisplatin emulsified with Lipiodol (ethiodized oil) and then occluded with Gelfoam pledgets; and drug-eluting bead TACE (DEB-TACE) using calibrated microspheres that absorb and controllably elute doxorubicin over 1-2 weeks. TACE is the standard-of-care treatment for BCLC stage B hepatocellular carcinoma (intermediate, multinodular) per EASL and AASLD guidelines, extending median survival from approximately 16 months with supportive care to approximately 26 months.

TACE is indicated rather than associated with a specific causative disease. Its primary indication is hepatocellular carcinoma (HCC), the most common primary liver cancer globally. HCC develops predominantly in the setting of cirrhosis from any etiology: chronic hepatitis B virus (HBV) infection (most common HCC cause globally, especially in Asia and Sub-Saharan Africa), chronic hepatitis C virus (HCV) infection, alcoholic cirrhosis, non-alcoholic steatohepatitis (NASH/NAFLD — the fastest-growing HCC risk factor in Western countries), autoimmune liver disease, and hereditary hemochromatosis. Other indications for TACE include liver-dominant metastases from neuroendocrine tumors (hepatic arterial therapy achieves objective response in 50-80% of NETs with liver metastases), colorectal liver metastases (DEBIRI-TACE with irinotecan-loaded beads), cholangiocarcinoma, and intrahepatic cholangiocarcinoma. Bridge therapy to liver transplantation maintains transplant candidacy and prevents HCC progression while awaiting a donor organ.

HCC presenting with BCLC-B disease eligible for TACE may be asymptomatic — detected on surveillance ultrasound in cirrhotic patients — or may present with right upper quadrant pain or fullness, fatigue, and mild weight loss. Post-procedure symptoms (post-embolization syndrome): right upper quadrant pain and tenderness at the TACE site occurring within 4-12 hours, fever (38-39°C), nausea, and marked fatigue — occurring in up to 80% of patients and typically lasting 3-7 days. Elevated liver function tests (transaminases, bilirubin) are expected post-procedure. Serious procedure-related complications are uncommon but include: liver abscess (less than 2%), bile duct injury with biloma formation (less than 2%), non-target embolization causing cholecystitis or gastric ulceration (less than 1%), and hepatic decompensation in patients with borderline liver reserve.

BCLC staging is essential before TACE: BCLC-B (intermediate) is the primary indication — multinodular HCC beyond Milan criteria (>1 nodule >5 cm, or >3 nodules, or >1 nodule 3-5 cm), preserved liver function (Child-Pugh A-B7), adequate performance status (ECOG 0-1), no vascular invasion, no extrahepatic spread. Pre-procedure assessment: liver function (Child-Pugh score), portal vein patency (crucial — main portal vein thrombosis contraindicates TACE), AFP (alpha-fetoprotein) as HCC marker, and assessment of total tumor volume and distribution. CT angiography or diagnostic hepatic angiogram maps the arterial anatomy. Response assessment 4-6 weeks after TACE uses mRECIST on contrast-enhanced MRI (arterial-phase enhancing viable tumor) rather than RECIST (size). Complete response (CR) = no viable enhancement; partial response (PR) = ≥30% reduction in viable tumor diameter.

TACE procedure: performed under conscious sedation or general anesthesia in an angiography suite; a 5-French sheath is placed in the femoral artery; selective catheterization of the hepatic artery using a 5-French catheter and coaxial 2.0-2.7Fr microcatheter; tumor-selective (sublobar) embolization is preferred over lobar TACE to preserve liver function; cTACE: doxorubicin 50-75 mg in Lipiodol emulsion followed by Gelfoam pledgets; DEB-TACE: LC-Bead LUMI or DC-Bead loaded with doxorubicin 75-150 mg (DEB-TACE provides better local tolerability and similar efficacy to cTACE per the PRECISION V trial). Combination strategies: TACE plus sorafenib (TACTICS trial: PFS benefit), TACE plus lenvatinib (LAUNCH trial), and sequential TACE followed by atezolizumab-bevacizumab (EMERALD-1 trial) — combinations aim to extend overall survival beyond TACE monotherapy. On-demand TACE (retreatment only for confirmed viable residual or recurrent tumor) is now preferred over scheduled TACE. TACE is also used as bridge therapy to liver transplantation to maintain HCC within Milan criteria.

Prognosis for BCLC-B hepatocellular carcinoma treated with TACE has improved substantially. Two landmark randomized controlled trials (Llovet et al. and Lo et al., Lancet 2002) established that TACE extends median overall survival from approximately 16 months with supportive care to approximately 26-29 months. Patients achieving complete radiological response by mRECIST criteria (no viable arterial-phase tumor enhancement) have markedly better outcomes — median OS exceeding 40-50 months compared to approximately 15-20 months for non-responders. Response to initial TACE session is the most important predictor of ongoing treatment utility and guides the decision to continue or switch to systemic therapy. Key prognostic factors include Barcelona Clinic Liver Cancer (BCLC) stage, Child-Pugh liver function score (Child-Pugh A significantly better than B), alpha-fetoprotein level, tumor burden (number, size, and total tumor volume), absence of vascular invasion, and AFP response after the first TACE (ART and HAP scores). Combination TACE plus sorafenib (TACTICS trial) improved median time-to-progression from 13.5 to 25.2 months. Successful downstaging of HCC to within Milan criteria with TACE enables transplant listing, with post-transplant 5-year OS exceeding 70-75% — the best achievable outcome for this patient group. Patients with Child-Pugh C or main portal vein thrombosis have very poor prognosis and should not receive TACE. Long-term monitoring requires contrast-enhanced MRI using mRECIST every 4-6 weeks after each TACE session, regular liver function tests, and AFP measurement every 4-8 weeks to guide treatment decisions.

Prevention of HCC — the primary indication for TACE — is highly effective. Hepatitis B vaccination prevents HBV infection and associated cirrhosis and HCC; universal neonatal HBV vaccination in endemic countries has dramatically reduced HCC incidence. Antiviral therapy for chronic HBV (tenofovir disoproxil or entecavir) reduces HCC risk by approximately 50% in cirrhotic patients. Sustained virological response following direct-acting antiviral (DAA) therapy for HCV reduces HCC risk by approximately 70%. Alcohol cessation halts alcoholic cirrhosis progression. NASH prevention through lifestyle measures — weight loss, physical activity, and management of metabolic syndrome — reduces NAFLD-associated HCC risk. For patients with established cirrhosis regardless of etiology: biannual liver ultrasound with AFP measurement per EASL guidelines enables early HCC detection at small, potentially curable sizes before patients require palliative TACE.

Patients with liver cirrhosis should maintain their scheduled biannual ultrasound surveillance for HCC detection — early HCC is treated curatively by resection, ablation, or transplantation; once HCC progresses to BCLC-B or -C, outcomes are substantially worse. Seek prompt evaluation for any patient with known cirrhosis who develops: new right upper quadrant pain; rising AFP values on surveillance; or a new hepatic lesion on surveillance ultrasound. Patients already on TACE therapy should attend their scheduled post-treatment MRI response assessment and return to the TACE team for any fever, right upper quadrant pain, or jaundice occurring after the expected 1-week post-embolization syndrome window — late complications such as liver abscess may present identically to post-embolization syndrome and require urgent treatment.